INS and metabolic syndrome: Empagliflozin has several adverse effects, including hypotension (especially in patients treated with ACE-inhibitors, ARBs or diuretics), acute kidney injury, genital mycotic infections, ketoacidosis, hypoglycemia in patients on insulin, dyslipidemia and extremely rarely, Fournier gangrene and peripheral amputations (Table 2) [40,41].